Company Overview
- Website
- rpharm-us.com
- Employees
- 3
- Industry
- Major Drugs
- SIC Code
-
2834 - Pharmaceutical Preparations
Financials & Stats
Revenue
$3B
Recent News & Media
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
- Jun 20, 2024
- nature.com
Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports
- Oct 4, 2022
- onlinelibrary.wiley.com
R-Pharm
- Aug 18, 2022
- crunchbase.com
Nowa kombinacja leków skuteczna u pacjentów z zaawansowanym rakiem jajnika
- Feb 15, 2022
- medexpress.pl
New Drug Combination Shown Effective for Patients With Advanced Ovarian Cancer
- Feb 13, 2022
- medicine.yale.edu
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer | British Journal of Cancer
- Feb 11, 2022
- nature.com
Companies Similar to RPharm US
Analyze industry trends and opportunities by examining competitors and companies comparable to RPharm US, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 3M | Houston, TX | 2016 | ||
| 3M | 21 | New York, NY | ||
| 3M | 6 | Chicago, IL | 2003 | |
| 3M | 16 | Tampa, FL | 2006 | |
| 3M | 7 | Phoenix, AZ |